BIOMAT Database Logo BIOMAT Database Logo

Effects of a new calcium channel blocker, TA 3090, on serum lipoprotein levels in mild to moderate essential hypertension. 1990

J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Fukuoka University Hospital, Japan.

The 25 hypertensive patients received 20 to 40 mg of TA 3090 daily for 12 weeks. Blood pressures declined significantly during treatment, from a mean of 162/98 to 145/88 mmHg. There were no significant changes in levels of total or very low-density lipoprotein cholesterol or triglyceride, in levels of low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, HDL2 cholesterol, HDL3 cholesterol, or in levels of apolipoprotein (apo) B, C-II, C-III, or E. Apo A-I and A-II levels increased significantly from 130 and 29.2 mg/dl before treatment to 152 and 31.4 mg/dl at 12 weeks. Mean serum creatinine levels decreased significantly from 0.92 to 0.80 mg/dl. No other drug-related changes in laboratory test results or side effects were noted. It is concluded that TA 3090 is a safe and effective treatment for mild to moderate hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
The effect of a new calcium channel blocker (TA-3090) on lipoprotein profile and intestinal lipid handling in rodents.
January 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Effects of calcium channel blockade on calcium homeostasis in mild to moderate essential hypertension.
September 1990, The American journal of the medical sciences,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Comparison of the efficacy of nicardipine, a new calcium channel blocker, with nifedipine in the treatment of mild to moderate essential hypertension.
June 1987, Postgraduate medical journal,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Effects of TA-3090, a new calcium channel blocker, on myocardial substrate utilization in ischemic and nonischemic isolated working fatty acid-perfused rat hearts.
March 1991, Circulation research,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Effects of pinacidil on serum lipid, lipoprotein, and apolipoprotein levels in patients with mild to moderate hypertension.
January 1990, Clinical therapeutics,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
[Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension].
January 1989, Anales de medicina interna (Madrid, Spain : 1984),
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Renal effects of bunazosin, a new alpha 1-adrenoceptor blocker, in patients with mild-to-moderate essential hypertension.
May 1990, Journal of cardiovascular pharmacology,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
June 1995, International journal of clinical pharmacology and therapeutics,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Treatment of mild-to-moderate hypertension: comparison between a calcium-channel blocker and a potassium-sparing diuretic.
January 1991, Journal of cardiovascular pharmacology,
J Sasaki, and M Ideishi, and K Saku, and K Arakawa, and K Tominaga, and Y Saeki, and N Otake, and K Kawasaki, and K Shirai, and I Sumida
Antihypertensive effect of a new calcium channel blocker, FK 235, in essential hypertension.
April 1986, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!